title: An in vivo model for screening peptidomimetic inhibitors of gelatinase A.
abstract: Gelatinase A, a matrix metalloproteinase, is frequently associated with human solid tumors, and its secretion and activation in the tumor milieu is considered important in the process of angiogenesis, invasion, and metastasis. Consequently, metalloproteinase inhibitors may be of value in the therapy of cancer as well as other disease states involving tissue remodeling and release of biologically active peptide/protein by proteolytic cleavage. Here we describe the development of a rapid screening assay for in vivo activity of peptidomimetic inhibitors of gelatinase A that involves assessment of inhibition of an enzyme-substrate reaction in a circumscribed body compartment, the mouse pleural cavity. As examples of the utility of this assay, in vivo activity of the aryl sulfonamide, sulfamyl urea, morpholino and carboxylic acid functionality at the P3' position of a series of hydroxamic acid inhibitors was examined after administration both intraperitoneally (ip) (to approximate systemic administration) and orally. For up to 2 h after ip administration, all inhibitors tested showed marked activity (> 90% inhibition) at 17 mumol/kg (approximately 10 mg/kg). This activity declined in a dose-responsive manner to insignificant levels at 0.67 mumol/kg (approximately 0.4 mg/kg). Aryl sulfonamides showed significant inhibition (> 50%) for up to 7 h after administration. A higher dosage (136 mumol/kg, approximately 80 mg/kg) was required to reveal oral activity, which was observed only with morpholino compounds (> 50% inhibition). Thus, the model described may be of value in the identification of orally active gelatinase A inhibitors.
authors.affiliation: Division of Oncology Biology, Celltech Ltd., Slough, U.K.
authors.forename: S K
authors.initials: SK
authors.lastname: Chander
authors.forename: P
authors.initials: P
authors.lastname: Antoniw
authors.forename: N R
authors.initials: NR
authors.lastname: Beeley
authors.forename: B
authors.initials: B
authors.lastname: Boyce
authors.forename: T
authors.initials: T
authors.lastname: Crabbe
authors.forename: A J
authors.initials: AJ
authors.lastname: Docherty
authors.forename: J
authors.initials: J
authors.lastname: Leonard
authors.forename: B
authors.initials: B
authors.lastname: Mason
authors.forename: K
authors.initials: K
authors.lastname: Millar
authors.forename: A T
authors.initials: AT
authors.lastname: Millican
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D018093:Gelatinases / Q000037:antagonists & inhibitors*; D006801:Humans; D007202:Indicators and Reagents; D007274:Injections, Intraperitoneal; D007700:Kinetics; D008297:Male; D020778:Matrix Metalloproteinase 2; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D051379:Mice; D010455:Peptides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D010994:Pleura / Q000378:metabolism; D051381:Rats
chemical_list: D007202:Indicators and Reagents; D010455:Peptides; D018093:Gelatinases; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2